glucagon has been researched along with ipragliflozin in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (ipragliflozin) | Trials (ipragliflozin) | Recent Studies (post-2010) (ipragliflozin) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 175 | 45 | 172 |
| Protein | Taxonomy | glucagon (IC50) | ipragliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 1.876 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0076 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
1 trial(s) available for glucagon and ipragliflozin
| Article | Year |
|---|---|
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |